Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Leonard Valentino: How We Protect Joints in People With Hemophilia
Leonard Valentino/LinkedIn
Jun 2, 2026, 17:34

Leonard Valentino: How We Protect Joints in People With Hemophilia

Leonard Valentino, President of WFH USA, shared a post on LinkedIn about a recent article by Clotilde Martin et al., published in Journal of Thrombosis and Haemostasis, adding:

“I am pleased to share out new research published in Journal of Thrombosis and Hemostasis on a potential shift in how we protect joints in people with hemophilia now available.

Chronic joint damage remains one of the most debilitating complications of hemophilia — even in the era of highly effective prophylaxis.

A newly published study by Martin et al. offers compelling preclinical evidence that targeting synovial inflammation, not just bleeding, may be key to preserving long-term joint health.

Recurrent bleeding ‘drives proliferation of synovial fibroblasts and activates innate and adaptive immune pathways,’ fueling a cycle of chronic synovitis and progressive cartilage destruction.

What the study explored:

Using a hemophilia B mouse model, we tested whether adding methotrexate (MTX) — a well‑established immunomodulator in rheumatoid arthritis — to extended half‑life FIX prophylaxis could:

  • Reduce synovial inflammation
  • Limit angiogenesis (the formation of new, fragile blood vessels)
  • Protect cartilage from early degeneration

Key Findings:

  • Whether used preventively or therapeutically, MTX plus000000 FIX:
  • Significantly reduced synovial hyperplasia
  • Lowered synovial vascularity — a major driver of recurrent bleeding
  • Decreased macrophage infiltration, a contributor to joint remodeling
  • Preserved cartilage proteoglycans when introduced early
  • Notably, once cartilage erosion was established, MTX could not reverse it — underscoring the importance of early intervention.

We highlight, MTX ‘limits cartilage damage and pathologic synovial angiogenesis,’ supporting its evaluation as a disease‑modifying adjunct therapy in hemophilic arthropathy.

Why this matters:

This study strengthens a growing paradigm shift:

  • Bleeding triggers joint damage, but inflammation drives its progression.
  • Addressing both pathways may offer better long‑term protection than factor therapy alone.

For clinicians, researchers, and patient communities, this opens the door to exploring short‑term, targeted immunomodulation as a complement to modern hemostatic therapies.

What’s next?

Translating these findings to humans will require careful clinical evaluation — particularly around dosing, timing, and safety.

But the concept is powerful:

Could hemophilic arthropathy become a preventable, modifiable condition rather than an inevitable outcome?

This study suggests the answer may be yes.”

Title: Targeting synovitis by immunomodulation as a novel therapeutic approach for hemophilic arthropathy

Authors: Clotilde Martin, Leonard A. Valentino, Lilou Martinez, Matthieu Souviraa-Labastie, Alexandre Leuci, Yesim Dargaud

Leonard Valentino

Stay updated on all scientific advances on Hemostasis Today.

Alexandre Leuci Clotilde Martin Health Hematology Hemostasis Hemostasis News Hemostasis Today Journal of Thrombosis and Hemostasis Leonard A. Valentino Lilou Martinez Matthieu Souviraa-Labastie Medicine Yesim Dargaud
NewsFeed